Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1)

Authors :: Johnson, Bruce E.
Kim, Tae Min
Hiltermann, T. Jeroen N.
Barlesi, Fabrice
Grohe, Christian
Goto, Yasushi
Gunnarsson, Orvar
Overbeck, Tobias
Reguart, Noemi
Wermke, Martin
Castro, Gilberto
Felip, Enriqueta
Greystoke, Alastair
Solomon, Benjamin J.
Nebot, Noelia
Deudon, Stephanie
Louveau, Anne-Laure
Passos, Vanessa Q.
Tan, Daniel S. W.
Translational Immunology Groningen (TRIGR)
Source :: Molecular cancer therapeutics, 18(12). AMER ASSOC CANCER RESEARCH
Publication Year :: 2019

Language :: English
ISSN :: 15357163
Database :: OpenAIRE
Journal :: Molecular cancer therapeutics, 18(12). AMER ASSOC CANCER RESEARCH
Accession number :: edsair.narcis........cc3c945922b4d1fc9784f086b07ea614

Tools